Legal & General Group PLC Tcr2 Therapeutics Inc. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$2.11 - $2.94 $5,023 - $7,000	-2,381 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $27,727 - $50,490	-6,054 Reduced 71.77%	2,381 $11,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $41,212 - $89,603	4,883 Added 137.47%	8,435 $72,000
Q2 2021 Aug 12, 2021	SELL	$16.41 - $24.71 $689 - $1,037	-42 Reduced 1.17%	3,552 $58,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $4,259 - $7,120	209 Added 6.17%	3,594 $80,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $22,249 - $38,209	1,171 Added 52.89%	3,385 $104,000
Q3 2020 Nov 13, 2020	BUY	$13.1 - $20.69 $1,362 - $2,151	104 Added 4.93%	2,214 $45,000
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $3,502 - $9,065	538 Added 34.22%	2,110 $32,000
Q1 2020 May 14, 2020	SELL	$6.01 - $16.01 $2,560 - $6,820	-426 Reduced 21.32%	1,572 $10,000
Q4 2019 Feb 13, 2020	BUY	$12.17 - $17.88 $511 - $750	42 Added 2.15%	1,998 $29,000
Q3 2019 Nov 13, 2019	BUY	$10.15 - $19.53 $14,321 - $27,556	1,411 Added 258.9%	1,956 $29,000
Q2 2019 Aug 14, 2019	BUY	$13.64 - $20.97 $7,433 - $11,428	545 New	545 $8,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.